These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 25437464)

  • 41. Liraglutide in oral antidiabetic drug combination therapy.
    Garber AJ
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():13-9. PubMed ID: 22405265
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incretin-based therapies and cardiovascular risk.
    Mannucci E; Dicembrini I
    Curr Med Res Opin; 2012 May; 28(5):715-21. PubMed ID: 22439700
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.
    Spellman CW
    J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S7-15. PubMed ID: 22267302
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incretin-based therapies: review of current clinical trial data.
    Peters A
    Am J Med; 2010 Mar; 123(3 Suppl):S28-37. PubMed ID: 20206729
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Incretin and incretin-based therapies].
    Harada N; Inagaki N
    Nihon Rinsho; 2010 May; 68(5):931-42. PubMed ID: 20446595
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Incretin-based antidiabetic treatment and diseases of the pancreas (pancreatitis, pancreas carcinoma)].
    Jermendy G
    Orv Hetil; 2016 Apr; 157(14):523-8. PubMed ID: 27017851
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
    Unger J
    J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):eS2-9. PubMed ID: 21389296
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gastrointestinal safety across the albiglutide development programme.
    Leiter LA; Mallory JM; Wilson TH; Reinhardt RR
    Diabetes Obes Metab; 2016 Sep; 18(9):930-5. PubMed ID: 27097971
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral Semaglutide (Rybelsus) for the Treatment of Type 2 Diabetes Mellitus.
    Semenya AM; Wilson SA
    Am Fam Physician; 2020 Nov; 102(10):627-628. PubMed ID: 33179892
    [No Abstract]   [Full Text] [Related]  

  • 50. Incretin-based therapy: Is the risk of pancreatitis driven by cardiovascular disease?
    Sohani ZN; Li L; Sun X
    Diabetes Res Clin Pract; 2016 Jul; 117():28-31. PubMed ID: 27329019
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comment on 'Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials'.
    Goldenberg RM
    Diabetes Obes Metab; 2024 Jul; 26(7):2997-2999. PubMed ID: 38576082
    [No Abstract]   [Full Text] [Related]  

  • 52. Pancreatitis and incretin-based drugs: clarity or confusion?
    Nauck MA; Meier JJ
    Lancet Diabetes Endocrinol; 2014 Feb; 2(2):92-3. PubMed ID: 24622699
    [No Abstract]   [Full Text] [Related]  

  • 53. Pioglitazone: are rumours of its death exaggerated?
    Gale EA
    Diabet Med; 2015 Apr; 32(4):431-7. PubMed ID: 25773280
    [No Abstract]   [Full Text] [Related]  

  • 54. Neither evidence from the PROactive study nor the KPNC supports pioglitazone as a tumour promoter.
    Ryder RE
    Diabet Med; 2015 Apr; 32(4):438-9. PubMed ID: 25773281
    [No Abstract]   [Full Text] [Related]  

  • 55. Do GLP-1-based therapies increase cancer risk?
    Nauck MA; Friedrich N
    Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S245-52. PubMed ID: 23882053
    [No Abstract]   [Full Text] [Related]  

  • 56. Use of GLP-1 mimetic in type 2 diabetes mellitus: is it the end of fragility fractures?
    Mabilleau G
    Endocrine; 2015 Feb; 48(1):1-2. PubMed ID: 25348148
    [No Abstract]   [Full Text] [Related]  

  • 57. A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy.
    George RE; Joseph S
    Saudi Pharm J; 2014 Nov; 22(5):403-10. PubMed ID: 25473328
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Safety and tolerability of GLP-1 receptor agonists].
    Soldevila B; Puig-Domingo M
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():35-40. PubMed ID: 25437464
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Safety and tolerability of GLP-1 receptor agonists].
    Soldevila B; Puig-Domingo M
    Med Clin (Barc); 2014; 143 Suppl 2():35-40. PubMed ID: 25326842
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.
    Aroda VR; Ratner R
    Diabetes Metab Res Rev; 2011 Sep; 27(6):528-42. PubMed ID: 21484979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.